<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RSS Feed]]></title><description><![CDATA[RSS Feed]]></description><link>https://ecency.com</link><image><url>https://ecency.com/logo512.png</url><title>RSS Feed</title><link>https://ecency.com</link></image><generator>RSS for Node</generator><lastBuildDate>Sat, 15 Aug 2026 20:24:23 GMT</lastBuildDate><atom:link href="https://ecency.com/created/nsclc/rss.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Treatments for ALK-Positive NSCLC]]></title><description><![CDATA[ALK-positive non-small cell lung cancer (NSCLC) is a subtype of lung cancer characterised by a genetic mutation in the anaplastic lymphoma kinase (ALK) gene. Several first-line treatments are available]]></description><link>https://ecency.com/@mrmed/treatments-for-alk-positive-nsclc</link><guid isPermaLink="true">https://ecency.com/@mrmed/treatments-for-alk-positive-nsclc</guid><category><![CDATA[mrmed]]></category><dc:creator><![CDATA[mrmed]]></dc:creator><pubDate>Wed, 31 Jul 2024 09:34:48 GMT</pubDate></item><item><title><![CDATA[Targeted Therapies For ALK-Positive Non-small Cell Lung Cancer]]></title><description><![CDATA[One of the most common and fatal types of cancer in the world continues to be lung cancer. The most prevalent form of lung cancer, non-small cell lung cancer (NSCLC), is characterised by its heterogeneity,]]></description><link>https://ecency.com/@mrmed/targeted-therapies-for-alk-positive</link><guid isPermaLink="true">https://ecency.com/@mrmed/targeted-therapies-for-alk-positive</guid><category><![CDATA[mrmed]]></category><dc:creator><![CDATA[mrmed]]></dc:creator><pubDate>Wed, 30 Aug 2023 09:01:57 GMT</pubDate></item><item><title><![CDATA[New 2020 study shows CBD & THC treat LUNG CANCER]]></title><description><![CDATA[A 2020 Spanish study found CBD and THC treat the most common type of lung cancer. Non-small lung carcinomas (NSCLC) represents 85% of all lung cancers. Both canabinoid agonists (THC and CBD) alone, and]]></description><link>https://ecency.com/@medikatie/new-2020-study-shows-cbd-and-thc-treat-lung-cancer</link><guid isPermaLink="true">https://ecency.com/@medikatie/new-2020-study-shows-cbd-and-thc-treat-lung-cancer</guid><category><![CDATA[hive-195708]]></category><dc:creator><![CDATA[medikatie]]></dc:creator><pubDate>Tue, 19 May 2020 00:21:12 GMT</pubDate><enclosure url="https://i.ecency.com/p/RGgukq5E6HBNvuPpuJoWwmDPPkGx4aaF7Xp3vKda4cwCFKNyYyj7qAXStR8XSEbW7xpZ9Nb2x4c3qUbQ6ECogm1vBFnKEezxcvzYMGDEKa9oepq6kRV2ubGuAgP8VZY?format=match&amp;mode=fit" length="0" type="false"/></item><item><title><![CDATA[Noxalk Ceritinib in Natco, India, is only 5% of the price in the United States.]]></title><description><![CDATA[Ceritinib (trade name Zykadia ) is a prescription-only drug used for the treatment non-small cell lung cancer (NSCLC). It was developed by Novartis and received FDA approval for use in April 2014. Zykadia]]></description><link>https://ecency.com/@wonzr/noxalk-ceritinib-in-natco-india-is-only-5-of-the-price-in-the-united-states</link><guid isPermaLink="true">https://ecency.com/@wonzr/noxalk-ceritinib-in-natco-india-is-only-5-of-the-price-in-the-united-states</guid><category><![CDATA[ceritinib]]></category><dc:creator><![CDATA[wonzr]]></dc:creator><pubDate>Fri, 21 Jun 2019 12:22:54 GMT</pubDate><enclosure url="https://i.ecency.com/p/qjrE4yyfw5pEPvDbJDzhdNXM7mjt1tbr2kM3X28F6SraZdLJL3dC7e1tcrpKnup96oUAoiK2UAk6ufdHUhoH9WMkX9PTRsVmVqBn7KH1qEE4QsTtfUks3EGW?format=match&amp;mode=fit" length="0" type="false"/></item></channel></rss>